MX2018015722A - Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1). - Google Patents

Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).

Info

Publication number
MX2018015722A
MX2018015722A MX2018015722A MX2018015722A MX2018015722A MX 2018015722 A MX2018015722 A MX 2018015722A MX 2018015722 A MX2018015722 A MX 2018015722A MX 2018015722 A MX2018015722 A MX 2018015722A MX 2018015722 A MX2018015722 A MX 2018015722A
Authority
MX
Mexico
Prior art keywords
antisense oligonucleotides
expression
htra1 expression
modulating
modulating htra1
Prior art date
Application number
MX2018015722A
Other languages
English (en)
Inventor
Iacone Roberto
Ottosen Søren
Hagedorn Peter
PEDERSEN Lykke
Kammler Susanne
Traustason Sindri
Hudlebusch Heidi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018015722A publication Critical patent/MX2018015722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Abstract

La presente invención se refiere a oligonucleótidos (oligómeros) antisentido que son complementarios a HTRA1, que conducen a la modulación de la expresión de HTRA1. La modulación de la expresión de HTRA1 resulta beneficiosa para un abanico de trastornos médicos, tales como la degeneración macular, por ejemplo la degeneración macular asociada a la edad.
MX2018015722A 2016-07-01 2017-06-28 Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1). MX2018015722A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16177508 2016-07-01
EP17170129 2017-05-09
PCT/EP2017/065937 WO2018002105A1 (en) 2016-07-01 2017-06-28 Antisense oligonucleotides for modulating htra1 expression

Publications (1)

Publication Number Publication Date
MX2018015722A true MX2018015722A (es) 2019-05-27

Family

ID=59295175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015722A MX2018015722A (es) 2016-07-01 2017-06-28 Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).

Country Status (21)

Country Link
US (2) US10519450B2 (es)
EP (1) EP3478839A1 (es)
JP (3) JP7060525B2 (es)
KR (1) KR20190025970A (es)
CN (1) CN109415732B (es)
AU (1) AU2017289204A1 (es)
BR (1) BR112018077321A2 (es)
CA (1) CA3026855A1 (es)
CL (1) CL2018003698A1 (es)
CO (1) CO2018013240A2 (es)
CR (1) CR20180606A (es)
IL (1) IL263489A (es)
MA (1) MA45620A (es)
MX (1) MX2018015722A (es)
PE (1) PE20190381A1 (es)
PH (1) PH12018502707A1 (es)
RU (1) RU2019101298A (es)
SG (2) SG11201811554SA (es)
TW (1) TW201803990A (es)
WO (1) WO2018002105A1 (es)
ZA (1) ZA201808291B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
BR112018077321A2 (pt) 2016-07-01 2019-04-24 F. Hoffmann-La Roche Ag oligonucleotídeos anti-sentido para modular a expressão de htra1
EP3728590A1 (en) 2017-12-22 2020-10-28 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
BR112020010090A2 (pt) 2017-12-22 2020-11-03 Roche Innovation Center Copenhagen A/S oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos
AU2018386524A1 (en) 2017-12-22 2020-07-02 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
EP3752612A4 (en) 2018-02-12 2021-11-10 Ionis Pharmaceuticals, Inc. MODIFIED COMPOUNDS AND USES THEREOF
WO2020007772A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020109343A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020109344A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2341057A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
WO2000008134A2 (en) 1998-08-03 2000-02-17 Novartis Ag HUMAN HtrA SERINE PROTEASE
AU758956B2 (en) 1999-02-12 2003-04-03 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP1888083B1 (en) 2005-05-24 2011-12-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to lmw-ptpase
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
DK2044223T3 (da) * 2006-07-26 2012-10-08 Univ Yale Inc Diagnosticering og behandling af aldersrelateret makuladegeneration
WO2008067040A2 (en) * 2006-10-06 2008-06-05 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2097448A4 (en) 2006-12-22 2010-07-21 Univ Utah Res Found METHOD FOR DETECTING DISEASES AND OCULAR DISEASE CONDITIONS AND TREATMENT THEREOF
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
TW200911290A (en) * 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
CA2704809A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
CN104136451A (zh) 2011-09-07 2014-11-05 玛瑞纳生物技术有限公司 具有构象限制的单体的核酸化合物的合成和用途
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2850184A4 (en) 2012-05-16 2016-01-27 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
BR112018077321A2 (pt) 2016-07-01 2019-04-24 F. Hoffmann-La Roche Ag oligonucleotídeos anti-sentido para modular a expressão de htra1
JP7033591B2 (ja) 2016-11-11 2022-03-10 ロシュ イノベーション センター コペンハーゲン エーエス 治療用オリゴヌクレオチドの捕捉および検出
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression

Also Published As

Publication number Publication date
BR112018077321A2 (pt) 2019-04-24
JP7060525B2 (ja) 2022-04-26
RU2019101298A (ru) 2020-08-03
US10519450B2 (en) 2019-12-31
TW201803990A (zh) 2018-02-01
CO2018013240A2 (es) 2018-12-14
PH12018502707A1 (en) 2019-11-11
US20180002701A1 (en) 2018-01-04
JP7416852B2 (ja) 2024-01-17
CA3026855A1 (en) 2018-01-04
JP2019522987A (ja) 2019-08-22
CN109415732B (zh) 2024-01-02
CR20180606A (es) 2019-02-14
ZA201808291B (en) 2019-10-30
JP2022106785A (ja) 2022-07-20
US20200399641A1 (en) 2020-12-24
WO2018002105A1 (en) 2018-01-04
MA45620A (fr) 2019-05-08
SG10202005885VA (en) 2020-07-29
AU2017289204A1 (en) 2019-01-17
RU2019101298A3 (es) 2021-01-26
CL2018003698A1 (es) 2019-04-05
IL263489A (en) 2019-01-31
PE20190381A1 (es) 2019-03-08
KR20190025970A (ko) 2019-03-12
SG11201811554SA (en) 2019-01-30
JP2024029178A (ja) 2024-03-05
CN109415732A (zh) 2019-03-01
EP3478839A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
PH12018502707A1 (en) Antisense oligonucleotides for modulating htra1 expression
PH12020500252A1 (en) Compounds as modulators of ror gamma
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
PH12019502636A1 (en) Antisense oligonucleotides for modulating htra1 expression
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2017004645A (es) Derivados de benzotiofenilo como agonistas de gpr40 para el tratamiento de la diabetes tipo ii.
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
PH12016501613B1 (en) Pyrazines modulators of gpr6
PH12018501019A1 (en) Diamino pyridine derivatives
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2016011630A (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.
AR112908A1 (es) Oligonucleótidos antisentido para modular la expresión de htra1
MX2017008162A (es) Sintesis total de trioxacarcina dc-45-a2 y preparacion de analogos de trioxacarcina.